Mike Ricciardi serves as Associate Director of Translational Research at George Washington University, Director of Product Development at Mabloc, LLC, and President of Miami Medical Consulting Corp. In these roles, he leads the development of research and commercial products from laboratory to clinical application.

His work focuses on monoclonal antibodies (mAbs) and their applications in treating and diagnosing diseases including Dengue, Zika, Yellow Fever, Coronaviruses, Influenza, Herpes, and HIV. Over the past decade, mAbs have become highly sought-after therapeutics due to their specificity and tolerability, with advances in single-cell cloning, next-generation sequencing, and rapid screening accelerating their development.

Mike developed the Broadly Reactive Antibody Isolation and Development (BRAID) platform, combining viral vectors, mRNA-LNP technology, molecular biology tools, immunology techniques, and machine learning. This indication-agnostic platform enables Mabloc to rapidly isolate and develop mAbs for both infectious diseases and targets in inflammatory disease and oncology, bringing critical medicines to underserved patient populations.